Protopanoxadiol derivative as well as preparation method and application thereof

A technology of protopanaxadiol and derivatives, applied in the direction of drug combination, pharmaceutical formula, steroid compound, etc.

Pending Publication Date: 2021-11-12
山东铂源生物医药有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the clinical application of PD-L1 and PD-1 monoclonal antibodies has achieved good results,...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protopanoxadiol derivative as well as preparation method and application thereof
  • Protopanoxadiol derivative as well as preparation method and application thereof
  • Protopanoxadiol derivative as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The preparation of the protopanaxadiol valine ester of embodiment 1.Boc protection

[0025]

[0026] Dissolve 1.89g of Boc-protected valine in 40mL of Py, then add 1.66g of EDCI into it, activate it at room temperature for half an hour, then add 0.80g of DMAP, 1g of protopanaxadiol in sequence, and raise the temperature after the addition The reaction was carried out at 40°C. After reacting for 10 hours, the reaction solution was concentrated under reduced pressure to remove part of pyridine, and the remaining viscous material was added to 50 mL of EA, then washed twice with 50 mL of 10% dilute hydrochloric acid, and washed twice with 50 mL of saturated Na 2 CO 3 The solution was washed twice, and washed once with 40 mL of saturated brine, and the organic layer was dried over anhydrous sodium sulfate. Suction filtration and concentration under reduced pressure gave 1.8 g of a yellow solid.

Embodiment 2

[0027] Embodiment 2. The preparation of protopanaxadiol valine ester

[0028]

[0029] Dissolve 0.8g of the solid obtained in the previous step in a mixed solvent of 6mL toluene and 4.5mL isopropanol, replace the argon protection, drop the temperature to -10°C, add 0.2mL methanesulfonic acid dropwise, and react at 50°C for eight hours , adding 10 mL of EA, followed by washing with 10 mL of saturated sodium carbonate solution three times, and once with 10 mL of saturated brine, and drying the organic layer over anhydrous sodium sulfate. Suction filtration and concentration under reduced pressure gave 0.6 g of the crude product, which was eluted with ethyl acetate / petroleum ether (16%–50%) through silica gel column chromatography to obtain 0.3 g of 3-Val-PPD protopanaxadiol valine derivative. g, yield 44%, and C 20 0.35g of dehydrated 3-Val-PPD protopanaxadiol valine derivative. The yield is 50%.

Embodiment 3

[0030] Embodiment 3. The preparation of protopanaxadiol valine ester hydrochloride

[0031]

[0032] Purified 0.3g 3-Val-PPD and C 20 The dehydrated 0.35g 3-Val-PPD protopanaxadiol valine derivative was dissolved in ethyl acetate, added the ethyl acetate solution of HCl, precipitated, and was filtered by suction to obtain the corresponding protopanaxadiol valine Acid derivative hydrochloride 0.3g and C 20 0.35 g of dehydrated protopanaxadiol valine derivatives.

[0033] 3-Val-PPD proton spectrum and mass spectrum data are as follows:

[0034] 1 H-NMR (600MHz, CDCl 3 ): δ5.17(t, J=7.2Hz, 1H), 4.53(dd, J 1 =11.6Hz,J 2 =4.9Hz,1H),3.60(td,J 1 =10.4Hz,J 2 =5.2Hz,1H),3.33-3.26(m,1H),2.17(s,1H),2.14-1.99(m,4H),1.91-1.80(m,2H),1.70(s,3H),1.64( s,3H),1.58-1.38(m,7H),1.33-1.24(m,6H),1.20(s,3H),1.16-1.06(m,3H),1.03-0.98(m,6H),0.92- 0.86(m,15H).ESI-MS(m / z):560.5[M+H] + .

[0035] C 20 -dehydrated 3-Val-PPD: ESI-MS(m / z): 542.4[M+H] + .

[0036] 3,12-diVal-PPD: ESI-MS(m / z)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a protopanoxadiol derivative and a preparation method thereof, application of the protopanoxadiol derivative as a medicine for treating cancers, and application of the protopanoxadiol derivative in combination with a PD-L1/PD-L2 antibody to improvement of an anti-tumor treatment effect on lung cancers and reduction of side effects. Cancer can be effectively treated through treatment of the combined medicine.

Description

technical field [0001] The present invention relates to a protopanaxadiol derivative, its preparation method and application, and the application of the protopanaxadiol derivative and PD-L1 / PD-L2 antibody in the preparation of medicines for treating cancer. Background technique [0002] Programmed death-1 (PD-1) is a transmembrane receptor on T cells, which was first obtained by subtractive method in apoptotic T cell hybridomas. It is named because it participates in apoptosis. PD-1 can interact with ligands PD-L1 and PD-L2 to inhibit T cell proliferation. PD-L1 and PD-L2 are mainly expressed on antigen-presenting cells (such as DC cells and macrophages). Although the clinical application of PD-L1 and PD-1 monoclonal antibodies has achieved good results, so far, the response rate of cancer patients to PD-L1 and PD-1 monoclonal antibodies is only about 20-30% . Finding a combination drug that improves the clinical response rate of PD-L1 and PD-1 monoclonal antibodies has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07J41/00A61K31/575A61K39/395A61P35/00
CPCC07J41/0088A61K31/575A61K39/39558A61P35/00A61K2300/00
Inventor 刘珂陈国良范华英寇丽娟刘明
Owner 山东铂源生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap